SEC Form 13F
| Report period | 2024-09-30 |
|---|---|
| Publicly available | 2024-11-15 |
| Reported value | $331,044,132 |
| Positions | 54 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| SPDR SER TR | XBI | S&P BIOTECH | $29,640,000 | 300,000 |
| BIOHAVEN LTD | Unresolved | CALL | $17,428,437 | 348,778 |
| SAREPTA THERAPEUTICS INC | SRPT | COM | $14,986,800 | 120,000 |
| NOVO-NORDISK A S | NVO | ADR | $13,097,700 | 110,000 |
| BLUEPRINT MEDICINES CORP | BPMC | COM | $12,950,000 | 140,000 |
| AXSOME THERAPEUTICS INC | AXSM | COM | $12,132,450 | 135,000 |
| TARSUS PHARMACEUTICALS INC | TARS | COM | $11,511,500 | 350,000 |
| PERSPECTIVE THERAPEUTICS INC | CATX | COM NEW | $10,012,500 | 750,000 |
| CG ONCOLOGY INC | CGON | COM | $9,432,500 | 250,000 |
| ROIVANT SCIENCES LTD | ROIV | SHS | $9,232,000 | 800,000 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.